Although outcomes for patients with NSCLC have improved over the past 20 years with enhanced radiation protocols and targeted therapies such as immune checkpoint inhibitors (ICIs) and EGFR inhibitors, tumors often develop resistance to these agents [3, 4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.